Nuvectis Pharma (NASDAQ:NVCT) Shares Down 5.2% - Here's What Happened

Key Points

• Nuvectis Pharma shares fell 5.2% to about $24.53 in mid-day trading, with volume down 74% from the average daily level.
• Analyst sentiment remains broadly positive, with three Buy ratings and one Sell rating; the consensus is “Moderate Buy” with a $35 target price.
• The company reported a quarterly loss of $0.30 per share, missing estimates by $0.04, while CEO Ron Bentsur and major shareholder Marlio Charles Mosseri recently purchased additional shares.

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) fell 5.2% during mid-day trading on Wednesday . The company traded as low as $24.27 and last traded at $24.5340. Approximately 43,397 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 166,446 shares. The stock had previously closed at $25.89.

Analysts Set New Price Targets

NVCT has been the topic of several analyst reports. Weiss Ratings upgraded shares of Nuvectis Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 20th. Roth Capital lifted their price objective on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the company a "buy" rating in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Nuvectis Pharma from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. UBS Group set a $33.00 target price on shares of Nuvectis Pharma in a research report on Monday, July 6th. Finally, Cantor Fitzgerald started coverage on Nuvectis Pharma in a report on Monday. They set an "overweight" rating on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Nuvectis Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.00.

Nuvectis Pharma Price Performance

The firm has a fifty day simple moving average of $20.07 and a 200 day simple moving average of $13.01. The company has a market cap of $802.00 million, a price-to-earnings ratio of -18.80 and a beta of -0.26.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). Analysts expect that Nuvectis Pharma, Inc. will post -0.98 earnings per share for the current year.

Insider Buying and Selling at Nuvectis Pharma

In other news, major shareholder Marlio Charles Mosseri bought 50,000 shares of the business's stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, with a total value of $916,000.00. Following the transaction, the insider directly owned 3,186,576 shares in the company, valued at approximately $58,378,072.32. The trade was a 1.59% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Ron Bentsur purchased 12,500 shares of the firm's stock in a transaction on Tuesday, June 30th. The shares were purchased at an average price of $20.00 per share, with a total value of $250,000.00. Following the completion of the acquisition, the chief executive officer directly owned 3,688,424 shares of the company's stock, valued at approximately $73,768,480. This trade represents a 0.34% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 28.55% of the company's stock.

Institutional Trading of Nuvectis Pharma

Several hedge funds have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in Nuvectis Pharma by 376.8% in the 2nd quarter. California State Teachers Retirement System now owns 3,991 shares of the company's stock valued at $73,000 after buying an additional 3,154 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Nuvectis Pharma during the second quarter worth approximately $5,057,000. Stonepine Capital Management LLC bought a new stake in shares of Nuvectis Pharma in the second quarter valued at approximately $735,600,000. Bank of America Corp DE bought a new stake in shares of Nuvectis Pharma in the second quarter valued at approximately $218,000. Finally, Legal & General Group Plc bought a new stake in shares of Nuvectis Pharma in the second quarter valued at approximately $31,000. Institutional investors own 96.77% of the company's stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source